A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 7, 2013, Pages 899-906

  Park, K K ^a   Wu, J J ^a   Koo, J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ADULT; ARTICLE; BODY MASS; BODY SURFACE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; MAINTENANCE DRUG DOSE; MALE; MONOTHERAPY; NARROW BAND IMAGING; OBESITY; OUTCOME ASSESSMENT; PHOTOTHERAPY; PHOTOTHERAPY DEVICE; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; ULTRAVIOLET THERAPY; YOUNG ADULT;

EID: 84879117065     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04611.x     Document Type: Article

References (28)

1. Koo J,. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-496.
2. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
3. Huerta C, Rivero E, Rodriguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-1565.
4. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
5. Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 2011; 159: 577-583.
6. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
7. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingard E, Stahle M,. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
8. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
9. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
10. Strober BG, Gottleib A, Leonardi C, Papp K,. 'Levels of response of psoriasis patients with different baseline characteristics treated with etanercept [Abstract]'. J Am Acad Dermatol 2006; 54: AB220.
11. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54: S101-S111.
12. Puig L,. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-1011.
13. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-1721.
14. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-175.
15. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7: 245-253.
16. De Simone C, D'Agostino M, Capizzi R, Capponi A, Venier A, Caldarola G,. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol 2011; 21: 568-572.
17. Do AN KJ,. Initiating narrow-band UVB for the treatment of psoriasis. Psoriasis Forum 2004; 10: 7-11.
18. Lynde CW, Gupta AK, Guenther L, Poulin Y, Levesque A, Bissonnette R,. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat 2011; doi: 10.3109/09546634.2011.607795 [Epub ahead of print].
19. Zhou SY, Shu C, Korth-Bradley J, et al. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol 2011; 51: 864-875.
20. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
21. Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol 2011; 12: 51-62.
22. Reich K MA, Plotnick M, Guzzo C, Li S, Gottlieb AB,. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. Psoriasis Forum 2007; 13: 21-26.
23. De Simone C, Carbone A, Caldarola G,. Etanercept therapy for psoriasis in a patient with numerous comorbidities. Am J Clin Dermatol 2010; 11 (Suppl 1): 49-50.
24. Lee E, Koo J, Berger T,. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005; 44: 355-360.
25. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS,. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931-935.
26. Jo SJ KH, Choi MR, Youn JI,. No evidence for increased skin cancer risk in Koreans with skin phototypes III-V treated with narrowband UVB phototherapy. Acta Derm Venereol 2011; 91: 40-43.
27. Black RJ, Gavin AT,. Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data. Br J Dermatol 2006; 154: 566-567.
28. Kamangar F, Neuhaus I, Koo J,. Skin cancer rates on biologic therapies. J Dermatolog Treat 2011; doi: 10.3109/09546634.2011.652064 [Epub ahead of print].